Danaher's New CEO Says Growth Fell Short Of Portfolio's 'Full Potential' And Names Share Gain Her 'Report Card'

Julie Sawyer Montgomery says the portfolio rebuild is largely done and the job now is commercial execution and tighter deal discipline.

Share
Danaher's New CEO Says Growth Fell Short Of Portfolio's 'Full Potential' And Names Share Gain Her 'Report Card'

Danaher CEO Julie Sawyer Montgomery told analysts on the company's third-quarter earnings call that growth over the past several years "has not consistently reflected the full potential of our portfolio." In her first call in the job, she said the portfolio overhaul is "largely complete" and the focus now moves to getting more growth out of the businesses Danaher already owns.

The reset she laid out

Montgomery described the opportunity as becoming "the defining leader in life sciences and diagnostics." She named four priorities: commercial excellence, innovation, talent and capital allocation, and called commercial execution the most immediate one.

She said the focus is shifting "from reshaping the portfolio to delivering more growth from the businesses we own." She also said credibility "will be earned through results."

The quarter itself came in ahead of management's expectations. Core revenue growth excluding respiratory revenue improved to 5.5%, and adjusted operating margin was 29%, CFO Matt Gugino said. Sales were $6.6 billion, and Danaher raised its full-year adjusted earnings guidance to $8.57 to $8.62 per share, from $8.45 to $8.60. Danaher shares traded at $217.59, down about 3% from the prior close, in Wednesday trading.

What analysts pressed on

Asked by a UBS analyst what investors should track, Montgomery said "unambiguous share gain" is the team's "true report card," alongside higher and profitable core growth.

She framed the change as a response to customers. When the old Harvard case study was written, she said, customers typically bought from one operating company; today the same customers buy across three, six or 12. Diagnostics solutions teams, she said, have created "several hundred millions of dollars of opportunity in a short time."

An analyst from Milius Research asked how she would change sales behavior. She said no one's incentives should be hurt when a solutions team calls on customers, and she is "happy to double pay on incentives."

On M&A, an analyst noted that some past deals underperformed and that other companies freeze after mistakes. Montgomery replied, "We certainly don't want to freeze." She said the company has learned from the misses and wants "strategically compounding" deals, and that recent purchases including StatLab and Masimo fit that test.

The numbers behind 2027

Gugino said 4% to 5% core growth excluding respiratory revenue is "the right starting point" for 2027, matching the range of recent quarters, and that a quantitative outlook will come in January. A Jefferies analyst asked why growth would not accelerate; Montgomery pointed to the planning process in the fourth quarter. The MarketWatch report covers the quarter's results.

She also said respiratory revenue planning stays at $1.5 billion this year and is the starting point for next year.

On reshoring of US bioprocessing capacity, she said it "could be a billion dollar market opportunity in the US," but expects it to play out over several years, mostly starting in 2028. Bioprocessing orders grew mid-teens in the quarter.

Danaher will give its quantitative 2027 outlook in January.

Sources

More on Danaher

All Danaher (DHR) coverage →